BELLUS Health Inc. (BLUSF)

[screamingeagle]

It has come down . Could be a bargain?

[lstedr_adv]

i ve been wathching since 1.55...still up now...good to buy now

[surf1944]

Neurochem Faces Kiacta Hurdle in Europe
Friday December 14, 9:17 am ET
Neurochem Gets Negative European Recommendation on Its Kidney Condition Drug Kiacta

NEW YORK (AP) -- Biotechnology company Neurochem Inc. said Friday a European advisory committee recommended against approving the company's troubled kidney condition treatment.

The drug, called Kiacta, will likely need to go through an additional study, according to the Committee for Medicinal Products for Human Use. The committee advises the European Medicines Agency and is similar to an advisory committee for the U.S. Food and Drug Administration.

Kiacta is aimed at treating Amyloid A amyloidosis, which can eventually destroy organs, including the kidneys. Half of all people diagnosed with the condition die within five years.

The FDA has twice asked the company for more information on the drug in order to consider it for approval. The agency accepted the company's latest response and a decision on the drug's status is scheduled for April 2.

Neurochem said it is considering requesting a re-examination of the European committee's opinion. If the request is made, there could be a decision by the second quarter, the company said.

[surf1944]

Neurochem announces European opinion for Eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis
Friday December 14, 8:24 am ET

ECUBLENS, Switzerland, Dec. 14 /PRNewswire-FirstCall/ - Neurochem (International) Limited (Neurochem), a wholly-owned subsidiary of Neurochem Inc. (NASDAQ: NRMX - News; TSX: NRM - News), announces that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), has issued a negative opinion recommending refusal of the marketing authorization application (MAA) for eprodisate (KIACTA(TM)) for the treatment of Amyloid A (AA) amyloidosis and concluding that another study would be needed to demonstrate eprodisate's (KIACTA(TM)) effectiveness. The Company is currently reviewing all of its options in view of this opinion, including the option of requesting a re-examination of the opinion by CHMP. As provided by the European regulations, the Company may request that the CHMP consult a Scientific Advisory Group (SAG) in connection with the re-examination. The deadline for filing any such request is within fifteen days of receipt of notification of the opinion.women and the elderly, along with a study comparing it to a drug already on the market, before it can approve it for sale.

http://biz.yahoo.com/prnews/071214/mo412.html?.v=2

[Minddoc7]

Canada Hot Stocks To Watch: MPX.UN.T MBT.T NRMX SWS.UN.T -2-

Dec 7, 2007 09:07:36 (ET)

TORONTO (Dow Jones)--Below are the stocks expected to move during Friday's trading session. They are listed with Thursday's closing prices.

EXFO Electro-Optical Engineering Inc. (EXFO, C$5.50, C$0.23, 4.4%) expects 1Q GAAP EPS of nil a share, below its guidance for earnings of 1-4c. Gross margin is expected to fall below expectations. Desjardins and RBC cut their target prices on the stock following the news.

Le Chateau Inc. (CTU.A.T, C$13.50, C$0.50, 3.8%) said 3Q net rose to C$0.39 a share from C$0.34 and sales rose 5.5% to C$82.1M. Same-store sales increased 0.4%. Versant raised its rating to strong buy from buy and boosted its target price to C$19.75 from C$16.50.

Gildan Activewear Inc. (GIL, $39.35, $1.95, 5.2%) said 4Q net jumped to 34c a share from 14c. Adjusted earnings were 38c versus 30c. It confirmed fiscal 2008 earnings guidance of $1.85 a share.

IMAX Corp. (IMAX, $4.64, C$0.01, 0.2%) has signed a 100-theater deal with AMC Entertainment for the installation of digital projection systems at AMC locations in 33 major U.S. markets.

Impax Energy Services Income Trust (MPX.UN.T, C$2.30, C$0.08, 3.6%) is suspending its monthly cash distributions and reviewing further alternatives to reduce costs.

Manitoba Telecom Services Inc. (MBT.T, C$45.00, C$0.25, 0.6%) projects 2008 EPS of C$2.95-C$3.15 a share and revenue of C$1.92B-C$1.98B. Also sees EBITDA up 1-3%.

Neurochem Inc. (NRMX, C$2.78, -C$0.04, -1.4%) said the U.S. FDA has acknowledged that its response to the July 2007 approvable letter for the NDA for eprodisate (KIACTA) for the treatment of Amyloid A amyloidosis is a complete, Class 2 response.

Swiss Water Decaffeinated Coffee Income Fund (SWS.UN.T, C$7.00, C$0.25, 3.7%) said a key customer is continuing to experience significant delays in receiving its 4Q contracted Colombian coffees from a key supplier. Swiss Water said this will reduce its projected 4Q process volumes.

(MORE TO FOLLOW) Dow Jones Newswires

December 07, 2007 09:07 ET (14:07 GMT)

[surf1944]

Neurochem announces eprodisate (KIACTA(TM)) receives acknowledgement of complete response and is granted Class 2 review
Thursday December 6, 5:09 pm ET

ECUBLENS, Switzerland, Dec. 6 /PRNewswire-FirstCall/ - Neurochem (International) Limited (Neurochem), a wholly-owned subsidiary of Neurochem Inc. (NASDAQ: NRMX - News; TSX: NRM - News), announces that the Company has received an acknowledgement from the United States Food and Drug Administration (FDA) that Neurochem's response to the July 2007 approvable letter for the New Drug Application (NDA) for eprodisate (KIACTA(TM)) for the treatment of Amyloid A (AA) amyloidosis is a complete, Class 2 response. The PDUFA (Prescription Drug User Fee Act) goal date by which the FDA is expected to render a decision is April 2, 2008.

The NDA for approval of eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis was filed in February 2006. The Company submitted its response to the second approvable letter last September and this response has been acknowledged as complete by the FDA, allowing for the Class 2 review.

"We look forward to further productive interactions with the FDA as we enter late-stage discussions on our marketing application," said Dr. Francesco Bellini, Neurochem Inc.'s Chairman, President and CEO.

About eprodisate (KIACTA(TM))

Eprodisate (KIACTA(TM)) was investigated in an international, randomized, double-blind, placebo-controlled, and parallel-designed Phase II/III clinical trial in which 183 AA amyloidosis patients were enrolled at 27 sites around the world (Eprodisate for AA Amyloidosis Trial, EFAAT). Patients who completed the clinical trial were eligible for enrollment in an ongoing open-label extension study, some of whom have now been receiving eprodisate (KIACTA(TM)) for more than six years.

In September 2006, the European Medicines Agency (EMEA) confirmed that it had commenced a regulatory review of eprodisate (KIACTA(TM)). The Marketing Authorization Application is being reviewed under the Agency's centralized procedure. This means that an authorization from this Agency would apply to all 27 European Union member states, as well as to Norway and Iceland. An oral hearing occurred with the EMEA in November 2007 to discuss outstanding issues raised with respect to the eprodisate (KIACTA(TM)) application and a decision from the EMEA is expected by year-end, or shortly thereafter.

The Company also filed for marketing approval for eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis in Switzerland. A decision is expected in 2008.

Eprodisate (KIACTA(TM)) has received orphan drug status in the United States, the European Union and in Switzerland.

Neurochem Inc. sponsored the EFAAT study.

About Amyloid A (AA) Amyloidosis

A progressive and fatal condition, AA amyloidosis occurs in a proportion of patients with chronic inflammatory disorders, chronic infections and inherited diseases such as familial Mediterranean fever. The kidney is the organ most frequently affected and progression to dialysis/end-stage renal disease is the most common clinical manifestation in this disease. Currently, there is no approved therapy to treat AA amyloidosis and about half of all patients diagnosed with the disease die within five years of diagnosis.

http://biz.yahoo.com/prnews/071206/mo278.html?.v=1

[Minddoc7]

We have some late news.

Neurochem announces eprodisate (KIACTA(TM)) receives acknowledgement of complete response and is granted Class 2 review
Thursday December 6, 5:09 pm ET

[Minddoc7]

Look at all the markets. They are also correcting big time. GLTA!

[BYUINSDER]

Ouch!!11% sell off...down we go..

[BYUINSDER]

Looks like lights out party over...best to save your capital..the ride down is going to low....

Junk stock...

[surf1944]

I post these little clips from seekingalpha.com, because they are usually well written, but mainly since they are widely read by traders. To me the NRMX trading pattern is looking for an upcoming event, but is also being helped by heavy short covering.

[Minddoc7]

surf, saw that article early Friday morning & thought we would be in for a bad day, but it didn't seem to damper NRMX trading. Interesting!

[surf1944]

Analysts Slash Neurochem Targets On Failed Alzheimer’s Drug
posted on: November 13, 2007 | about stocks: NRMX

The last-ditch efforts by biotech developer Neurochem Inc. (NRMX) to salvage some value from the US$150-million it has sunk into failed Alzheimer’s disease treatment Alzhemed played out last week like the Monty Python Dead Parrot sketch. Abandoning any further work to prove Alzhemed works according to the scientific standards of the food and drug regulators (which have so far branded results from human clinical trials as “inconclusive”), Laval, Qc.-based Neurochem plans to launch it as an off-the-shelf, unregulated “nutraceutical” to compete with such wonder non-drugs as Gingko Biloba.

Philippa Flint of RBC Capital Markets doesn’t buy it; this parrot (i.e. Alzhemed) is no more, has ceased to be, expired and gone to meet its maker.

“We see the nutraceutical strategy reinforcing our view that Alzhemed cannot withstand the rigors of good quality scientific research,” she wrote in a report, noting that the company has yet to establish the subsidiary, hire management or establish a strategy to get its consumer product to market, where it would have to fight for shelf space.

“We recommend investors sell their shares.”

She values the company at little more than its cash on hand, giving its shares a target price of US$1.50, less than half their closing price on Friday.

Piper Jaffray analyst Caroline Stewart’s limbo pole is even lower, with a price target of US50¢. And UBS analyst Annabel Samimy belatedly followed her peers, cutting her stock price target to US$1 from US$4.50 and declared the outlook for Alzhemed “grim.”

To which Neurochem CEO Dr. Francesco Bellini might respond, “Alzhemed isn’t dead; it’s just stunned.”

He rejects the unkind views of analysts as well as the standards of drug regulators for Alzheimer’s treatments. He insists he can scare up US$1-billion-plus in sales on store shelves for his unproven wonder treatment he claims works to slow the onset of memory loss in patients, even if the science hasn’t backed him up.

http://seekingalpha.com/article/53976-analysts-slash-neurochem-targets-on-failed-alzheimers-drug

[Minddoc7]

Finished the week green. Setting up nicely. Waiting patiently and holding. GLTA!

[BYUINSDER]

Friday close will be the option expiration deadline for Nov....

Short term it could go either way..up or down...

Long term....it sure feels like up is the trend.

O.T. Barry Bonds story is a shocker...the outcome might produce somekind of riots from the people If he is sent to prison...what the odds are is not clear..but its going to be very interesting....

The worldby the tail and hes in serious problems with the law..what gives?

God bless

[BYUINSDER]

Neurochem is basing (once again) at $3.68 level....pulling back from $4.01 level....The markup to $4.01 yesterday was done on about 45,000 shares.....

Someone is picking up shares...is it a another (bought deal) who knows..but they certainly want to bring the price upwards.

Volume totals on the pullbacks are very low...

Friday is option expiration day....

Put to Call ratio will play big time in which direction we close on friday...

Neurochem is kinda being (born again) its putting off the old ways of doing things and now doing things the right way..which will certainly payoff for everyone.

FDA kinda put Neurochem management in the right direction.

Without a real P-Value result above .05 level...it would foolish to allow the drug to be placed on the market.....

Lets see how the Kiacata drug results pan out..

You know them by their fruits...I think Walnuts are very healthy for the brain...

Eating a proper diet really is the key to success....

God bless

[BYUINSDER]

I'm leaning toward Walnuts..because I know lots of older people who eat walnuts everyday and they are still very sharp..

I used to give walnuts to my dogs it would somehow make them smarter...

[BYUINSDER]

Todays news item...does anyone have any type of clues to what types of food items that Neurochem has been using to make their drugs?

I'm thinking Apples might contain it..

Well, here is there chance to bring the stock up...

Lets see If they drop the ball or what..

God bless

[BYUINSDER]

Short covering at its best...Neurochem options expire on Friday (Two trading left)

This stock (Or investment) is high risk play.

Due to it has no real products to market...

Pure crap shoot......

I really can't wait until I'm fully out of this stock...

Lets pray its sooner than later...

God Bless

[Minddoc7]

Looks like we got some press in today's edition of The Motley Fool, which resulted in the surge:

Neurochem's Crazy Choice
By Brian Lawler November 14, 2007

I didn't think it was possible for a drugmaker to look more unscrupulous than Telik (Nasdaq: TELK) did earlier this year, but I apparently wasn't following Neurochem (Nasdaq: NRMX) closely enough.

In conjunction with its third-quarter earnings release last week, Neurochem announced that it would try to market its Alzheimer's disease drug candidate, ALZHEMED, as a dietary supplement in the U.S. and Canada, following a failed phase 3 study earlier in the year.

Unlike therapeutic drugs, the FDA cannot restrict the marketing of a compound that has been deemed a dietary supplement. But in order to get this designation, a compound must be a food substance and present in the food supply.

Neurochem's stance is that since the active ingredient in ALZHEMED (tramiprosate) "occurs naturally in certain foods," the FDA will allow its marketing as a supplement or "nutraceutical," as Neurochem calls it.

In conjunction with its attempted launch of ALZHEMED as a dietary supplement, Neurochem is halting its ongoing phase 3 study of the drug. (Hey, why let evidence-based medicine get in the way of allowing a good supplement onto the market?)

Neurochem's plan is to start selling the drug in the next 12 months, if the FDA gives the OK. Of course, it wouldn't be able to market ALZHEMED, the dietary supplement, as a treatment for Alzheimer's disease in the U.S.

Neurochem's other drug candidate, KIACTA, also faces an uncertain future (to put things politely). Neurochem filed a response to the FDA's second approvable letter in September and is awaiting word from the FDA.

Neurochem's CEO said last week that the company was "not going to comment on such things" when asked what new information about KIACTA was in the latest response. Anyone want to bet whether the FDA will fully approve KIACTA in the next several months?

[BYUINSDER]

We hit $4.00 from $3.40 basing....Yes...its ready to climb.

God bless

[BYUINSDER]

Just popped to $3.50 from $3.40 wow...


Something (Huge) must be happening

[BYUINSDER]

Basing at $3.40 level 9:40 am...acting as If something (HUGE) is about to unfold.

Neurochem is going to shake up the world soon...

[BYUINSDER]

Very interesting chart pattern....trading today light...(shorting) to set the final leg for the bull run....

Holidays are here....it sure would be sweet and wonderful If they could mark it up...price wise..

God bless

[Minddoc7]

Choppy, but ended green. Still waiting for the PR that will ignite the run. GLTA!

[BYUINSDER]

30 minute traders....the price has now moved above the 30 minute highs....

looks like so far...prices will continue there trend higher.

God bless

[BYUINSDER]

Traders will not be very happy (IF) this stock trades below the $3.25 mark.....

$3.25 marks the lower support channel......

Something better happen soon...Or Neurochem sharevalue is going to trade well below the $3.25 support levels.

Neurochem Stock options do expire on November 16....so we have 4 more trading days.....

Will the market makers who make up the options market on Neurochem squeez out the bears?

The current mood is bearish....

Put to Call ratio......

Which way will the stock price swing from here?

[BYUINSDER]

Todays trading seem rather odd....

Like the stock wanted to wait for somekind of big news in the future....

Interesting..trading ...Inside day ?

"Success often consists of going from failure to failure without loss of enthusiasm. " Elzabeth Taylor

[BYUINSDER]

Low today was $3.31 High was $3.52

Together $3.31 + $3.52 = $6.83

$6.83 divided by 2 = $3.415

Close today $3.43

So we closed above the 50% mark.....

Insider trading day?

We may be set to move upwards from here.....

[BYUINSDER]

Today trading (Insider trading day?) or not?

Centocor Inc. has been wanting to take the Kiacta drug to the public...with its $6,000,000 upfront payment...If they get FDA green light...

Generic name is (Eprodisate)

[BYUINSDER]

My live charts data quote.com is showing the Insiders interest has fallen to under 29.985% and the Inst holders inst is at 10.31%

So the Inst are picking up shares why?

And why is the insiders selling?

Is this somekind of new financing deal?

Is this some kind of buyout?

Lets watch the data new few weeks..

[Minddoc7]

IMO, no matter how much we differ in our interpretations of these PRs, NRMX is acting very much like a stock wanting to run hard. GLTA!

[BYUINSDER]

Conference call said the exact samething...

Canada needs to understand the USA FDA is put in place to serve the Aerican public..to serve and protect.

President Bush Jr. and V.P. offices are put in place to serve the people..not companies..

If a drug is not good for the Aerican public safety...its the job of the FDA to stop it..

Now this canada firm wants to bring it to market without FDA green light..

Fat chance

[surf1944]

Neurochem Plans To Revive Failed Alzheimer's Drug
posted on: November 09, 2007 | about stocks: NRMX

Seeking to prove there are second acts in the lives of biotech startups, Neurochem Inc. (NRMX) now plans to market its Alzheimer's drug, Alzhemed, as an off-the-shelf "nutraceutical" after failing to win approval from the U.S. Food and Drug Administration.

Neurochem, headed by Dr. Francesco Bellini, said Thursday it would stop European human clinical trials after the FDA earlier found a similar, two-and-a-half year study in the U.S. yielded “inconclusive” results on the drug’s efficacy in stopping the onset of memory loss from the disease. To get the FDA nod, new trials would be needed, adding years and millions more in costs to a process that has already eaten up C$150-million in spending by the company.

The FDA news in August sent Neurochem stock crashing by 44% to C$3.30 and led analysts to conclude the firm was worth no more than cash on hand.

Cracking the code on the fatal brain-wasting disease has been one of the top pursuits in drug research, and Dr. Bellini had predicted a US$4.5-billion per year market for Alzhemed. Ever the optimist, however, Dr. Bellini has decided the effects of Alzhemed aren’t so inconclusive after all. He says demand from patients and clinicians who insist the drug works should lead to robust sales for the treatment, but as an unproven cure on par with Ginkgo Biloba, a plant-based memory remedy sold as a consumer product.

“If I didn’t believe [Alzhemed] worked I would not have done what I did,” he said. “I have a moral responsibility” to take it to market, which should happen in the next three to 12 months.

Now, Mr. Bellini predicts Alzhemed – which will be sold by a new subsidiary of Neurochem – will command C$1-billion or more in annual sales. He shooed away the ongoing skepticism of analysts and even took a swipe at the FDA, which he feels makes it too hard and costly for drug companies to get new treatments approved – especially those for Alzheimer’s.

That said, he’s hedging his bets. The firm also Wednesday said it would launch another test drug to treat Alzheimer’s into preclinical development.

The market’s reaction to all this was pretty ho-hum. The stock closed at C$3.31, unchanged on the day.

http://seekingalpha.com/article/53594-neurochem-plans-to-revive-failed-alzheimer-s-drug?source=yahoo

[BYUINSDER]

The Doctor himself did state its a$900,000,000 market..for the drug....his last words was "its very interesting"

I'm feeling in the next three months time period...share value from its lows $2.12 to $4.00 will markup higher.

A company best defence is (concealment) ....they are not showing us all their cards just yet..

They are concealing some advantage.....

Burn rate is oving lower....sales revenue is gaining...

The big picture...is looking much better..

[Kadaicher1]

I didnt get the good feeling from that CC you did. That they would take Alzhemed to a different company to sell as a naturaceutical says to me they have given up on it.

[BYUINSDER]

The November 8 2007 Conference Call was outstanding in my opinion.

We can't trun off our thinking powers just yet thats for sure.

Neurochem goal which is to market their lastest drugs...is having some degree of success....according to the conference call...

Johnson and Johnson sub company is marketing the Kiacata drug the way it sounds to me..but they just can't get FDA green light in the USA as of yet..

Thats going to be their greatest challenge......USA market.

Two of the woman who asked questions I was amazed at their IQ levels..pretty sharp woman....they both took the Doctor to the ropes.....until he said "No comment" No comment to their direct questions regarding the Market shelf space ect...and Kiacata drug timeline..

One thing is for sure..Management is going to change at Neurochem..this was made perfectly clear....

This also leads me to feel a buyout is in the workings..

One of the woman asked direct questions to this exact subject line.....

Something very very positive is certainly happening with Neurochem....what exactly their plans are is unclear to me..as of yet..

Why would they Neurochem change direction and form a new type of company....that markets drugs..with new type of CEO ect..when they could just sell out to a giant firm who has shelf space agreements already.....this woman was pushing the right questions about this issue when she was cut off..with no comment and we will address that issue in our conference call...ect..

I find that questioning by her to b awesome..she gets a A+

To formulate the exact perfect question is very hard feat..she did it...perfectly....

Remember, Johnson and Johnson has given $40,000,000 already to Neurochem through their Centor firm...that makes up part of the $70,000,000 capital they have..

Johnson and Johnson knows something....big...

There are small details in that conference call that make me excitied..

That call just kinda reinforces my feelings before...something big is brewing......

And thats what makes this game worth the risk....

P.S. I just love those two woman questions..theymade my week..

God bless

[BYUINSDER]

Neurochem Website has added a November 8th 2007 Conference page.

Go to their website...its in english and some other lingo..

Something odd is unfolding...

[BYUINSDER]

Sticking to the so-called (Topic) Neurochem Inc. common shares trading pattern is very (looking forward) in all respects.

Lets first observe the General markets, Dow, ect....

Trending downward huge amount of (Fear) within the mass trading public.

Its the perfect time period for the giants to shop for small up coming firms.

Almost (all) of this years 2007 gains in the NYA, Dow ect...are just about gone.

Or is that money flow (out) going to purchase other firms?

The last 30 minutes of trading Neurochem shares went upwards in value by $.18 per share..on only 5,000 shares.

After hours its flat..no change in price $3.50

ADX is saying something.....but what?

I've been trying to contact some V.I.P. in the investment industry..John Ailanjian but with no luck...John used to be number two man V.P. of very upscale investment banking firm in New York...

There is clearly something huge unfolding here..what it is a mystery at the current hour...but I'm going to get to the meat of it soon.

Matt Cramer has always said "Hitting a takeover stock is like hitting the Lotto"

John Ailanjian CFA changed jobs an dnow moved to Utah from New York City...he still works in the investment industry...with another firm..he has contacts....powerful contacts.

The chart pattern taking the whole picture in...the next big move in price ...is going to be upwards...how much of a movement is at question...still.

But with some luck...we might just might have picked a huge winner this year..

Today we open at $4.05 level....this stock wanted to run...but the general markets held it back..

Some of you may not know or understand the inner workings how much a powerful infusion of capital can do to a stock thats sooooooo undervalue...this stock is sooooo undervalue in terms of its lastest drugs....

Trading at $26 then crushed to $2.12 levels..

For what reasons?

Next week is going to be great...trust me I feel it in my bones..

[BYUINSDER]

CMF Money Flow is still in positive zone.

I'm really feeling (dreams) that someone huge is going to buyout Neurochem....

It clearly makes no sense what so ever..that not one of the giants have not even talked with Neurochem..

Why in the world not?

Froma pure business stance....its makes no sense..

[BYUINSDER]

The last 15 hours of trading ...strange..

It sells off with hourly bars that are very short in nature...at the top levels....

overlapping each selloff wave...

It really feels like it wants to trade higher....

Its like its waiting for something....

tsk tsk kind of feelings....

[BYUINSDER]

ADX is currently (above) both the Dmi- and Dmi +

Dmi + is still above the Dmi-

Very interesting set up..

I think some huge news item is about to come forth..

[BYUINSDER]

The news item today vs the news item last night...= Something strange is taking place.

Todays news item is clearly "Looking forward news"

With really o meat to hang your hat on..

Could potentially provide.......Could, maybe, might...not sure if it will..ect...

All left to chance....Comic irony gods..

I'm thinking Neurochem is hiding something.....like a buyout offer from a huge giant in the industry.

If they are so sure that in the near future, they can produce real cash flow from one of their drugs..why won't they try and sell that to a giant firm in the industry who needs new drugs.

Its kinda odd...

[Minddoc7]

NEWS:
http://biz.yahoo.com/prnews/071108/mo279.html?.v=3

[BYUINSDER]

Up in after hours trading to.."Trap" those who dot know better.

Who do you think makes those trades in after hours?

MM's do...

AS the shares drop in value...they gain money..or create money.

The mm's took the shares up soooo slowly..like the water temperature while a frog boils to death without jumping out.

Then they hit us with more negative news...

Down goes the value...

Who gains?

the mm's and the company gains.

Bull trap at its best..

[surf1944]

Last I checked this was an early stage biotech? You keep posting worthless dribble, NRMX was up in after hours trading. Stick with your .0001 pink sheet stocks and use your dog to pick them, the dog will do just as well as you.

[BYUINSDER]

I just checked the overnight Bid side of the equationthey are bidding $1.04 per share..the open is going to be ugly.

[BYUINSDER]

The $.58 per share is looking pretty interesting now..with Neurochem reporting more losses...

Wall Street is not going to be very happy thursday...

[surf1944]

Neurochem reports results for third quarter of fiscal 2007
Wednesday November 7, 6:55 pm ET
Neurochem will host a live web conference Thursday November 8, 2007, at 8:30 AM ET.

LAVAL, QC, Nov. 7 /PRNewswire-FirstCall/ - Neurochem Inc. (NASDAQ: NRMX - News; TSX: NRM - News) reported results for the third quarter ended September 30, 2007. Effective July 1, 2007, the Company adopted the US dollar as its functional and reporting currency, thus all figures reported are reported in US dollars, unless otherwise specified. The Company reported a net loss of $13,889,000 ($0.29 per share), compared to $16,509,000 ($0.43 per share) for the corresponding period in the previous year. For the nine-month period ended September 30, 2007, the net loss amounted to $65,389,000 ($1.54 per share), compared to $49,458,000 ($1.28 per share) for the same period last year.

The net loss for the nine-month period ended September 30, 2007, includes a non-recurring charge in the second quarter of fiscal 2007 under Canadian GAAP of $10,431,000 relating to the $40 million 5% senior subordinated convertible notes, which were fully converted into common shares during the second quarter of 2007.

Research and development (R&D) expenses amounted to $11,964,000 this quarter compared to $12,890,000 for the same period last year. For the nine-month period, R&D expenses were $43,533,000 compared to $37,546,000 for the corresponding period of the previous year. The increase in the nine-month period compared to the same period the previous year is due to expenses incurred in relation to the development of tramiprosate (ALZHEMED(TM)) primarily in respect of the ongoing Phase III clinical trial in Europe and the North American open-label extension of the Phase III study, as well as the conduct of a QT cardiac status Phase I study. Tramiprosate (ALZHEMED(TM)) is the Company's investigational product candidate for the treatment of Alzheimer's disease (AD).

As at September 30, 2007, the Company had available cash, cash equivalents and marketable securities of $70,637,000, compared to $48,758,000 at December 31, 2006. The increase is primarily due to proceeds received from the issue of convertible notes in May 2007 and is partially offset by funds used in operating activities.

http://biz.yahoo.com/prnews/071107/mo259.html?.v=3

[BYUINSDER]

You are 100% correct//

Adolf Coors III was the former heir to the Coors beer empire, (Ironically) Mr. Coors was ALLERGIC to beer.

How funny and odd.....

Basketball Star "Pistol" Pete Maravich told a Pennsylvania reporter, "I don't want to play 10 years (In the NBA) and then die of a heart atk when I'm 40."

Comic irony In 1988 he collapsed and died of a heart attack at ag 40, after playing exactly 10 NBA seasons.

How tragic and strange.....